Table 2. Detailed characteristics of patients and results of in vitro drug sensitivity tests with tumor cells isolated from ascites.

Patient		Clinical characteristics			Clinical outcome					In vitro outcome
Ps.	Age	FIGO stage	Type of chemotherapy	Surg.	Outcome surgery	CA125 level at diagnosis, E/mL	CA125 level at end of therapy, E/mL	Platinum sensitivity	BRCA mutation on tumor	GI50 carbo, μmol/L	GI50 cisplatin, μmol/L	GI50 paclitaxel nmol/L
1	71	IIIc	cis/taxa	PDS	Optimal	1154	10	Resistant	unknown		2.1	12
2	64	IIIc	carbo/tax	IDS	Complete	1800	34	Resistant	BRCA1	43.5		35
3	66	IIIc	cis/carbo/ taxa	PDS	Optimal	1242	5	Resistant	BRCA negative	80.6	20.6	12
4	64	IIIc	carbo/tax	PDS	Optimal	1481	15	Sensitive	unknown	77.9		10
5	64	IIIc	carbo/tax	PDS	Optimal	2400	26	Sensitive	unknown	90.7		14
6	55	IIIc	cis/taxa	PDS	Complete	67	11	Resistant	BRCA negative		11.8	45
7	68	IIIc	carbo/tax	None	N/A	3600	258	Resistant	BRCA negative	100.0		66
8	58	IVb	carbo/tax	IDS	Optimal	121	15	Resistant	BRCA negative	71.4		3
9	64	IVb	carbo/tax	IDS	Complete	1834	35	Sensitive	BRCA2	56.8		42
10	52	IVa	carbo/tax	IDS	Complete	1621	15	Sensitive	BRCA negative	100.0		35
11	50	IIIc	carbo/tax	IDS	Complete	2500	16	Sensitive	BRCA1	84.0		14
12	54	IIIc	carbo/tax	PDS	Optimal	351	14	Sensitive	BRCA negative	44.1		24
13	60	IIIc	carbo/tax	PDS	Optimal	500	8	Sensitive	BRCA negative	100.0		79
14	51	IVa	carbo/tax	IDS	Complete	3900	9	Sensitive	unknown	31.4		83

^aReceived at least one cycle of intraperitoneal chemotherapy with cisplatin. Abbreviations: Age, age at time of diagnosis; carbo, carboplatin; cis, cisplatin; GI₅₀, concentration of 50% cell growth inhibition; IDS, interval debulking surgery; PDS, primary debulking surgery; Ps., patient sample; Surg., surgery; tax, paclitaxel.